What is the difference between phase 1, 2, and 3 trials for Pancreatic Cancer

Pancreatic CancerMay 15, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Clinical Trial Phases for Pancreatic Cancer

Great question! Clinical trials are conducted in phases, and each phase has a specific purpose. Let me break down what makes each phase different:

Phase 1 Trials: Safety First

Phase 1 trials are the first studies done in humans. These are the smallest trials, typically involving 20-80 participants.

The main goals are:

Determine if a treatment is safe for people
Identify what dose patients can tolerate (how much medication is safe to give)
Watch for side effects and understand how severe they might be
Look for early signs that the treatment might be helpful

Think of Phase 1 as the "safety testing" stage. Researchers are essentially asking: "Is this drug safe enough to test further?"

Phase 2 Trials: Does It Work?

If Phase 1 data shows the treatment is safe, Phase 2 trials move forward. These are larger studies with 100-300 participants.

The main goals are:

Investigate who responds well to the treatment (which patients benefit most)
Continue collecting safety information
Evaluate how well the treatment works against pancreatic cancer
Serve as proof of concept — does this actually help patients?

Phase 2 is the "proof of concept" stage. Researchers are asking: "Does this treatment actually work for pancreatic cancer patients?"

Phase 3 Trials: Comparison to Standard Treatment

Phase 3 trials are the largest and most rigorous, typically involving 1,000-3,000 participants.

The main goals are:

Compare the new treatment to the current standard treatment (or a placebo)
Continue collecting data on safety and effectiveness
Evaluate side effects in a larger population
Determine if the new treatment is better than what we already have

According to the NCCN Guidelines for Patients: Pancreatic Cancer, Phase 3 trials are critical because if results are positive, the treatment may be approved by the FDA (U.S. Food and Drug Administration).

Phase 4 Trials: Long-Term Monitoring

After a drug is approved and on the market, Phase 4 trials (also called post-marketing surveillance) continue.

The goals are:

Monitor long-term safety of the approved treatment
Identify any new side effects that weren't seen in earlier trials
Understand how the treatment works in diverse populations

Why This Matters for Pancreatic Cancer Patients

According to the NCCN Guidelines, pancreatic cancer trials sometimes have extra "mini phases" within Phase 1 and Phase 2:

Phase 1a: Focuses on dose escalation — finding the right dose by gradually increasing or decreasing it
Phase 1b: The dose expansion phase — testing the dose identified in Phase 1a with more patients
Phase 2b: Expands on Phase 2 to see if the drug causes changes in the tumor itself or in lab test results

Key Takeaway

Each phase builds on the previous one:

Phase 1 = Is it safe?
Phase 2 = Does it work?
Phase 3 = Is it better than current treatment?
Phase 4 = What are the long-term effects?

According to the NCCN Guidelines, everyone with pancreatic cancer should carefully consider all treatment options available, including standard treatments and clinical trials. Talking to your doctor about whether a clinical trial makes sense for your specific situation is an important part of your treatment planning.